首頁EKSO • NASDAQ
add
Ekso Bionics
前次收盤價
$1.26
單日股價範圍
$1.27 - $1.38
一年股價範圍
$0.62 - $3.13
總市值
2453.55萬 USD
平均交易量
9.33萬
本益比
-
股利收益率
-
主要交易所
NASDAQ
市場新聞
財務資料
損益表
收益
淨利
(USD) | 2024年3月info | 逐年變化幅度 |
---|---|---|
收益 | 375.60萬 | -8.88% |
營業費用 | 520.70萬 | -19.25% |
淨利 | -342.90萬 | 21.87% |
淨利潤率 | -91.29 | 14.27% |
每股盈餘 | — | — |
營業資金流動 | -283.15萬 | 29.81% |
有效稅率 | — | — |
資產負債表
總資產
總負債
(USD) | 2024年3月info | 逐年變化幅度 |
---|---|---|
現金和短期投資 | 879.90萬 | -45.94% |
總資產 | 2895.70萬 | -21.96% |
總負債 | 1490.60萬 | -5.78% |
總權益 | 1405.10萬 | — |
流通股份 | 1741.90萬 | — |
股價淨值比 | 1.56 | — |
資產報酬率 | -28.13% | — |
資本報酬率 | -40.03% | — |
現金流量
現金變動淨額
(USD) | 2024年3月info | 逐年變化幅度 |
---|---|---|
淨利 | -342.90萬 | 21.87% |
營運現金 | — | — |
投資現金 | — | — |
融資現金 | — | — |
現金變動淨額 | — | — |
自由現金流 | — | — |
簡介
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
執行長
成立時間
2005
員工數
70